Association of Baseline Spinal Cord Area and Brain Volume With Long-Term Disability Progression in Ozanimod-Treated Participants With Relapsing Multiple Sclerosis: Final Analysis From the DAYBREAK Open-label Extension Study

被引：0

作者：

Filippi, Massimo ^{[1
,2
]}

Henry, Roland ^{[3
]}

Arnold, Douglas ^{[4
,5
]}

Granziera, Cristina ^{[6
,7
,8
,9
,10
,11
,12
,13
,14
]}

Kappos, Ludwig ^{[9
,10
,11
,12
,13
,14
]}

Sheffield, James ^{[15
]}

Cheng, Chun-Yen ^{[15
]}

Riolo, Jon ^{[15
]}

Pachai, Chahin ^{[15
]}

Cree, Bruce A. C. ^{[3
]}

机构：

[1] IRCCS San Raffaele Sci Inst, Neurol Unit, Div Neurosci, Neuroimaging Res Unit,Neurorehabil Unit, Milan, Italy

[2] Univ Vita Salute San Raffaele, Neurophysiol Serv, Milan, Italy

[3] Univ Calif San Francisco, Dept Neurol, Weill Inst Neurosci, San Francisco, CA USA

[4] McGill Univ, NeuroRx Res, Montreal, PQ, Canada

[5] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada

[6] Univ Hosp Basel, Dept Biomed Engn, Translat Imaging Neurol ThINk Basel, Fac Med, Basel, Switzerland

[7] Univ Basel, Basel, Switzerland

[8] Univ Hosp Basel, Dept Neurol, Basel, Switzerland

[9] Univ Hosp, Dept Headorgans Spine & Neuromed, Res Ctr Clin Neuroimmunol & Neurosci Basel RC2NB, Basel, Switzerland

[10] Univ Hosp, Dept Headorgans Spine & Neuromed, Res Ctr Clin Neuroimmunol & Neurosci Basel RC2NB, Basel, Switzerland

[11] Univ Hosp, Dept Clin Res, Res Ctr Clin Neuroimmunol & Neurosci Basel RC2NB, Basel, Switzerland

[12] Univ Hosp, Dept Biomed, Res Ctr Clin Neuroimmunol & Neurosci Basel RC2NB, Basel, Switzerland

[13] Univ Hosp, Dept Biomed Engn, Res Ctr Clin Neuroimmunol & Neurosci Basel RC2NB, Basel, Switzerland

[14] Univ Basel, Basel, Switzerland

[15] Bristol Myers Squibb, Princeton, NJ USA

来源：

MULTIPLE SCLEROSIS JOURNAL | 2024年 / 30卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P1451/510

引用

页码：922 / 923

页数：2

共 43 条

[1] Association of Baseline Spinal Cord Area and Brain Volume With Long-Term Disability Progression in Ozanimod-Treated Participants With Relapsing Multiple Sclerosis
Filippi, Massimo
Henry, Roland
Arnold, Douglas L.
Granziera, Cristina
Kappos, Ludwig
Sheffield, James
Chaudhry, Burhan
Cheng, Chun-Yen
Pachai, Chahin
Silva, Diego
Cree, Bruce
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 266 - 267
[2] Baseline Predictors of Long-Term Disability Progression in Ozanimod-Treated Participants With Relapsing Multiple Sclerosis
Hartung, Hans-Peter
DeLuca, John
Granziera, Cristina
Filippi, Massimo
Kappos, Ludwig
Cheng, Chun-Yen
Pachai, Chahin
Riolo, Jon
DeBoer, Erik
Silva, Diego
Penner, Iris-Katharina
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 354 - 355
[3] Baseline Whole Brain Volume and Disability Progression in Ozanimod-Treated Patients With Relapsing Multiple Sclerosis
Filippi, M.
Cohen, J. A.
Arnold, D. L.
Hartung, H. P.
Cheng, C. Y.
Pachai, C.
Riolo, J. V.
Silva, D.
Cree, B. A. C.
EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 183 - 183
[4] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: interim analysis of the DAYBREAK open-label extension study
Selmaj, K. W.
Steinman, L.
Comi, G.
Bar-Or, A.
Arnold, D. L.
Hartung, H. -P.
Montalban, X.
Havrdova, E. K.
Krakovich, A.
Sheffield, J. K.
Cheng, C. -Y.
Minton, N.
Silva, D.
Kappos, L.
Cohen, J. A.
Cree, B. A. C.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 359 - 360
[5] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: results from the DAYBREAK open-label extension study
Steinman, L.
Comi, G.
Bar-Or, A.
Selmaj, K. W.
Arnold, D. L.
Hartung, H. -P.
Montalban, X.
Havrdova, E. K.
Sheffield, J. K.
Minton, N.
Janjua, A.
Huang, V.
Silva, D.
Kappos, L.
Cohen, J. A.
Cree, B. A. C.
MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 548 - 549
[6] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: interim analysis of the DAYBREAK open-label extension study
Selmaj, K. W.
Steinman, L.
Comi, G.
Bar-Or, A.
Arnold, D. L.
Hartung, H. -P.
Montalban, X.
Havrdova, K.
Hoogerheyde, J.
Afsari, S.
Sheffield, J. K.
Shi, F.
Minton, N.
Silva, D.
Kappos, L.
Cohen, J. A.
Cree, B. A. C.
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 617 - 618
[7] Predictors of Relapse in Ozanimod-Treated Patients With Multiple Sclerosis: Ad Hoc Analysis From the Open-Label Extension DAYBREAK Study
Coyle, Patricia
Dunn, Jeffrey Dunn Jeffrey
Kappos, Ludwig
Cheng, Chun-Yen
Thorpe, Andrew
Morello, Jean Pierre
Silva, Diego
Filippi, Massimo
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 957 - 958
[8] Predictors of Relapse in Ozanimod-Treated Patients With Multiple Sclerosis: Post Hoc Analysis From the Open-Label Extension DAYBREAK Study
Coyle, Patricia
Dunn, Jeffrey
Kappos, Ludwig
Sheffield, James
Riolo, Jon
Cheng, Chun-Yen
Thorpe, Andrew
Filippi, Massimo
MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1036 - 1037
[9] Long-term Efficacy and Safety, Including COVID-19 Infections, Among Ozanimod-Treated Patients With Relapsing Multiple Sclerosis in the DAYBREAK Open-Label Extension Trial
Cree, B. A.
Selmaj, K. W.
Steinman, L.
Comi, G.
Bar-Or, A.
Arnold, D. L.
Hartung, H.
Montalban, X.
Havrdova, E. K.
Sheffield, J. K.
Minton, N.
Cheng, C.
Silva, D.
Kappos, L.
Cohen, J. A.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 85 - 86
[10] Safety of Concurrent Administration of Serotonergic Antidepressants and Ozanimod in Participants With Relapsing Multiple Sclerosis: Final Results From the DAYBREAK Open-label Extension Study
Naismith, Robert
Cohen, Jeffrey
Bar-Or, Amit
Comi, Giancarlo
Selmaj, Krzysztof
Hartung, Hans-Peter
Sheffield, James
Cheng, Chun-Yen
Riolo, Jon
Krakovich, Anthony
Reardon, Jennifer
Cree, Bruce A. C.
MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1029 - 1030

← 1 2 3 4 5 →